Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Forecast & News

$10.02
-0.18 (-1.76 %)
(As of 01/22/2020 08:26 AM ET)
Today's Range
$10.01
Now: $10.02
$10.32
50-Day Range
$8.92
MA: $9.76
$10.63
52-Week Range
$6.07
Now: $10.02
$20.21
Volume14.26 million shs
Average Volume13.08 million shs
Market Capitalization$10.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.85 billion
Cash Flow$4.55 per share
Book Value$15.53 per share

Profitability

Net Income$-2,150,000,000.00

Miscellaneous

Employees42,535
Outstanding Shares1,092,090,000
Market Cap$10.94 billion
Next Earnings Date2/12/2020 (Confirmed)
OptionableOptionable

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its quarterly earnings results on Thursday, November, 7th. The company reported $0.56 earnings per share for the quarter, missing analysts' consensus estimates of $0.58 by $0.02. The company earned $4.26 billion during the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. View Teva Pharmaceutical Industries' Earnings History.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Teva Pharmaceutical Industries.

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided EPS guidance of $2.30-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.38. The company issued revenue guidance of $$17.2-17.4 billion, compared to the consensus revenue estimate of $$17.18 billion.

What price target have analysts set for TEVA?

24 equities research analysts have issued 12 month target prices for Teva Pharmaceutical Industries' shares. Their forecasts range from $6.00 to $20.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $10.64 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.

What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 14 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

News stories about TEVA stock have trended very positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of 3.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Teva Pharmaceutical Industries.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 48)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Commerzbank Aktiengesellschaft FI (0.72%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), GFS Advisors LLC (0.01%) and Heritage Investors Management Corp (0.01%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Which major investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Zurcher Kantonalbank Zurich Cantonalbank , Janney Montgomery Scott LLC, Cacti Asset Management LLC, Hanson & Doremus Investment Management, Heritage Investors Management Corp, Addison Capital Co and IFM Investors Pty Ltd. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Luzich Partners Llc, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Which major investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was purchased by a variety of institutional investors in the last quarter, including Moon Capital Management LLC, DNB Asset Management AS, Wedbush Securities Inc., Huntington National Bank, GFS Advisors LLC and G&S Capital LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $10.02.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $10.94 billion and generates $18.85 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,245 (Vote Outperform)
Underperform Votes:  1,139 (Vote Underperform)
Total Votes:  2,384
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel